Vascular disruption in combination with mTOR inhibition in renal cell carcinoma

Leigh Ellis, Preeti Shah, Hans Hammers, Kristin Lehet, Paula Sotomayor, Gissou Azabdaftari, Mukund Seshadri, Roberto Pili

Research output: Contribution to journalArticle

Abstract

Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, there has been an increased interest in the use of antiangiogenic agents for the management of RCC in patients. However, the activity of tumor-vascular disrupting agents (tumor-VDA) has not been extensively examined against RCC. In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid, or vadimezan) in combination with the mTOR inhibitor everolimus (RAD001) against RCC. In vitro studies were carried out using human umbilical vein endothelial cells and in vivo studies using orthotopic RENCA tumors and immunohistochemical patient tumor-derived RCC xenografts. MRI was used to characterize the vascular response of orthotopic RENCA xenografts to combination treatment. Therapeutic efficacy was determined by tumor growth measurements and histopathologic evaluation. ASA404/everolimus combination resulted in enhanced inhibition of endothelial cell sprouting in the 3-dimensional spheroid assay. MRI of orthotopic RENCA xenografts revealed an early increase in permeability 4 hours posttreatment with ASA404, but not with everolimus. Twenty-four hours after treatment, a significant reduction in blood volume was observed with combination treatment. Correlative CD31/NG2 staining of tumor sections confirmed marked vascular damage following combination therapy. Histologic sections showed extensive necrosis and a reduction in the viable rim following combination treatment compared with VDA treatment alone. These results show the potential of combining tumor-VDAs with mTOR inhibitors in RCC. Further investigation into this novel combination strategy is warranted.

Original languageEnglish (US)
Pages (from-to)383-392
Number of pages10
JournalMolecular Cancer Therapeutics
Volume11
Issue number2
DOIs
StatePublished - Feb 2012
Externally publishedYes

Fingerprint

vadimezan
Renal Cell Carcinoma
Blood Vessels
Neoplasms
Heterografts
Therapeutics
Angiogenesis Inhibitors
Human Umbilical Vein Endothelial Cells
Blood Volume
Permeability
Necrosis
Endothelial Cells
Staining and Labeling

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Ellis, L., Shah, P., Hammers, H., Lehet, K., Sotomayor, P., Azabdaftari, G., ... Pili, R. (2012). Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. Molecular Cancer Therapeutics, 11(2), 383-392. https://doi.org/10.1158/1535-7163.MCT-11-0748

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. / Ellis, Leigh; Shah, Preeti; Hammers, Hans; Lehet, Kristin; Sotomayor, Paula; Azabdaftari, Gissou; Seshadri, Mukund; Pili, Roberto.

In: Molecular Cancer Therapeutics, Vol. 11, No. 2, 02.2012, p. 383-392.

Research output: Contribution to journalArticle

Ellis, L, Shah, P, Hammers, H, Lehet, K, Sotomayor, P, Azabdaftari, G, Seshadri, M & Pili, R 2012, 'Vascular disruption in combination with mTOR inhibition in renal cell carcinoma', Molecular Cancer Therapeutics, vol. 11, no. 2, pp. 383-392. https://doi.org/10.1158/1535-7163.MCT-11-0748
Ellis, Leigh ; Shah, Preeti ; Hammers, Hans ; Lehet, Kristin ; Sotomayor, Paula ; Azabdaftari, Gissou ; Seshadri, Mukund ; Pili, Roberto. / Vascular disruption in combination with mTOR inhibition in renal cell carcinoma. In: Molecular Cancer Therapeutics. 2012 ; Vol. 11, No. 2. pp. 383-392.
@article{f132dd95d18645d9969c65ce63691cc7,
title = "Vascular disruption in combination with mTOR inhibition in renal cell carcinoma",
abstract = "Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, there has been an increased interest in the use of antiangiogenic agents for the management of RCC in patients. However, the activity of tumor-vascular disrupting agents (tumor-VDA) has not been extensively examined against RCC. In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid, or vadimezan) in combination with the mTOR inhibitor everolimus (RAD001) against RCC. In vitro studies were carried out using human umbilical vein endothelial cells and in vivo studies using orthotopic RENCA tumors and immunohistochemical patient tumor-derived RCC xenografts. MRI was used to characterize the vascular response of orthotopic RENCA xenografts to combination treatment. Therapeutic efficacy was determined by tumor growth measurements and histopathologic evaluation. ASA404/everolimus combination resulted in enhanced inhibition of endothelial cell sprouting in the 3-dimensional spheroid assay. MRI of orthotopic RENCA xenografts revealed an early increase in permeability 4 hours posttreatment with ASA404, but not with everolimus. Twenty-four hours after treatment, a significant reduction in blood volume was observed with combination treatment. Correlative CD31/NG2 staining of tumor sections confirmed marked vascular damage following combination therapy. Histologic sections showed extensive necrosis and a reduction in the viable rim following combination treatment compared with VDA treatment alone. These results show the potential of combining tumor-VDAs with mTOR inhibitors in RCC. Further investigation into this novel combination strategy is warranted.",
author = "Leigh Ellis and Preeti Shah and Hans Hammers and Kristin Lehet and Paula Sotomayor and Gissou Azabdaftari and Mukund Seshadri and Roberto Pili",
year = "2012",
month = "2",
doi = "10.1158/1535-7163.MCT-11-0748",
language = "English (US)",
volume = "11",
pages = "383--392",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "2",

}

TY - JOUR

T1 - Vascular disruption in combination with mTOR inhibition in renal cell carcinoma

AU - Ellis, Leigh

AU - Shah, Preeti

AU - Hammers, Hans

AU - Lehet, Kristin

AU - Sotomayor, Paula

AU - Azabdaftari, Gissou

AU - Seshadri, Mukund

AU - Pili, Roberto

PY - 2012/2

Y1 - 2012/2

N2 - Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, there has been an increased interest in the use of antiangiogenic agents for the management of RCC in patients. However, the activity of tumor-vascular disrupting agents (tumor-VDA) has not been extensively examined against RCC. In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid, or vadimezan) in combination with the mTOR inhibitor everolimus (RAD001) against RCC. In vitro studies were carried out using human umbilical vein endothelial cells and in vivo studies using orthotopic RENCA tumors and immunohistochemical patient tumor-derived RCC xenografts. MRI was used to characterize the vascular response of orthotopic RENCA xenografts to combination treatment. Therapeutic efficacy was determined by tumor growth measurements and histopathologic evaluation. ASA404/everolimus combination resulted in enhanced inhibition of endothelial cell sprouting in the 3-dimensional spheroid assay. MRI of orthotopic RENCA xenografts revealed an early increase in permeability 4 hours posttreatment with ASA404, but not with everolimus. Twenty-four hours after treatment, a significant reduction in blood volume was observed with combination treatment. Correlative CD31/NG2 staining of tumor sections confirmed marked vascular damage following combination therapy. Histologic sections showed extensive necrosis and a reduction in the viable rim following combination treatment compared with VDA treatment alone. These results show the potential of combining tumor-VDAs with mTOR inhibitors in RCC. Further investigation into this novel combination strategy is warranted.

AB - Renal cell carcinoma (RCC) is an angiogenesis-dependent and hypoxia-driven malignancy. As a result, there has been an increased interest in the use of antiangiogenic agents for the management of RCC in patients. However, the activity of tumor-vascular disrupting agents (tumor-VDA) has not been extensively examined against RCC. In this study, we investigated the therapeutic efficacy of the tumor-VDA ASA404 (DMXAA, 5,6-dimethylxanthenone-4-acetic acid, or vadimezan) in combination with the mTOR inhibitor everolimus (RAD001) against RCC. In vitro studies were carried out using human umbilical vein endothelial cells and in vivo studies using orthotopic RENCA tumors and immunohistochemical patient tumor-derived RCC xenografts. MRI was used to characterize the vascular response of orthotopic RENCA xenografts to combination treatment. Therapeutic efficacy was determined by tumor growth measurements and histopathologic evaluation. ASA404/everolimus combination resulted in enhanced inhibition of endothelial cell sprouting in the 3-dimensional spheroid assay. MRI of orthotopic RENCA xenografts revealed an early increase in permeability 4 hours posttreatment with ASA404, but not with everolimus. Twenty-four hours after treatment, a significant reduction in blood volume was observed with combination treatment. Correlative CD31/NG2 staining of tumor sections confirmed marked vascular damage following combination therapy. Histologic sections showed extensive necrosis and a reduction in the viable rim following combination treatment compared with VDA treatment alone. These results show the potential of combining tumor-VDAs with mTOR inhibitors in RCC. Further investigation into this novel combination strategy is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84856851739&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84856851739&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0748

DO - 10.1158/1535-7163.MCT-11-0748

M3 - Article

VL - 11

SP - 383

EP - 392

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 2

ER -